Evariste Technologies

Evariste is a private UK-based AI-enabled oncology drug discovery company focused on synthetic lethal targets and biomarkers. The company uses its proprietary Frobenius platform to integrate multimodal biological data, machine learning, virtual screening, and physics-based modeling to identify targets and design small molecule therapeutics. Its lead internal program is a preclinical PKMYT1 inhibitor, EVT-0003023, aimed at precision oncology populations including non-small cell lung cancer, colorectal cancer, and ovarian cancer. Evariste also has earlier programs against VRK1 and additional undisclosed synthetic lethal targets, and it partners with pharmaceutical and academic groups to generate data and discover new oncology medicines.